News
Bioiberica has been assigned to the A group, which corresponds to companies having their own R&D center and production plant, with a significant volume of research.The biotech company invests close to13% of its profits into R&D, and during 2013 they intend to begin marketing their personalized medicine range of products for osteoarthritis treatment.
The ′Osteochip Project′ involded more than 1,700 post-menopause women aged 45 and older from France, Switzerland and Italy. This study is being developed by Bioiberica Farma, a leading Spanish biotechnology company with more than 30 years of experience in joint care under its belt. Dr.
The US Authorities inspected the facilities related to the production of heparin in the plants of Palafolls and Probisa.
Nearly 17% of the Andalusian population suffers from osteoarthritis, a disease that causes 35% of primary care visitsExperts will meet next Thursday in Malaga to discuss this disease and the role that pharmacists can play in monitoring its development
Bioiberica and Natural Ingredients signed an agreement for the marketing of Nucleoforce in Spain.